Rob Dillard

DocwireNews

The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in patients with cytopenic myelofibrosis (MF), according to a study that will be presented at the 2023 American Society of Clinical Oncology Annual Meeting.JAK inhibitor therapy can reduce both splenomegaly and disease symptoms in patients with MF; however, dosing is often limited in individuals with cytopenic MF due to drug-induced exacerbations of cytopenias. Pacritinib can be used at full dose in patients with MF, regardless of where they stand on the cytopenic spectrum.In this study, first author Prithviraj Bose and colleagues analyzed 276 patients who were treated with pacritinib in the PERSIST-1 and PERSIST-2 studies. The population of interest was stratified by baseline platelet (PLT; &lt;100, &ge;100&times;109/L) and hemoglobin (HB; &lt;8, 8 to &lt;10, &ge;10 g/dL) levels. The investigators then assessed depth of spleen volume response (SVR), modified total symptom score (TSS) response, patient global impression of change, and dose intensity.The findings showed that 80% of patients had &ge;10% SVR (SVR-10), over 75% had TSS-10, and nearly 80% reported reduced symptoms at week 24. Spleen reduction at week 24 occurred consistently across PLT and HB strata (84% to 93% and 86% to 90% of patients, respectively) the researchers noted. Moreover, SVR &ge;35% occurred in 23% to 25% of patients across PLT strata and in 21% to 28% of patients across HB strata. The researchers further observed that symptom response was consistent across strata, with no loss of symptom burden reduction in patients with thrombocytopenia. Overall, the findings demonstrated that across all subgroups, at least 75% of patients reported symptoms were &ldquo;improved&rdquo; at week 24.&ldquo;Pacritinib demonstrates consistent efficacy for spleen and symptom response in patients with MF regardless of blood counts. This consistent effect may be related to [the unique kinome profile of pacritinib] and its ability to be delivered at full dose in patients regardless of cytopenias,&rdquo; the researchers concluded.Source: Bose P, Gagelmann N, McLornan D, et al. Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis. Abstract #7068. Published for the 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, Illinois.

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Pacritinib Reduces Spleen Enlargement, Symptom Burden in Patients With Myelofibrosis

ASCO 2023

The novel JAK1-sparing inhibitor pacritinib is effective at reducing spleen enlargement and disease burden in MF patients.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe